Source: Annual Congress 2001 - Assessment and monitoring of inflammation in COPD and asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Dorini, A. Pelucchi, C. Leone, B. Mastropasqua, R. Guarnieri, A. Chetta, R. D'Ippolito, R. Testi, D. Olivieri, A. Foresi (Sesto S. Giovanni, Parma, Verona, Italy). Eosinophil apoptosis in induced sputum (IS) from patients with mild symptomatic asthma during treatment with Fluticasone propionate (FP). Eur Respir J 2001; 16: Suppl. 31, 2236

Member's Comments

No comment yet.

Related content which might interest you: Low doses of inhaled fluticasone propionate induce sputum eosinophil apoptosis and inhibit IL-5 release in naive symptomatic asthmatics (FLIC19) Source: Eur Respir J 2001; 18: Suppl. 33, 336s Year: 2001 Symptoms, induced sputum eosinophil percentages and treatment with salmeterol or fluticasone in mild asthmatics Source: Eur Respir J 2001; 18: Suppl. 33, 336s Year: 2001 Comparison of fluticasone propionate + salmeterol (FP+S) and montelukast (MK) on bronchial reactivity (BR), pulmonary function (PF) and clinical outcome in children with mild asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Fluticasone induces apoptosis in peripheral T-lymphocytes: a comparison between asthmatic and normal subjects Source: Eur Respir J 2002; 19: 257-266 Year: 2002 Efficacy of fluticasone furoate (FF)/vilanterol (VI) or FF alone in asthma patients with differing eosinophil (eos) levels Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Salmeterol/fluticasone propionate combination (SFC) improves airways hyperresponsiveness (AHR), lung function and symptoms in adult patients with mild asthma Source: Eur Respir J 2004; 24: Suppl. 48, 262s Year: 2004 Treatment with inhaled steroids in patients with symptoms suggestive of asthma but with normal lung function Source: Eur Respir J 2008; 32: 989-996 Year: 2008 Effects of salmeterol/fluticasone propionate (SFC) on airway inflammation in induced sputum in COPD Source: Annual Congress 2005 - Effects of anti-inflammatory drugs on COPD Year: 2005 Effect of switching from high dose fluticasone propionate (FP) to FP/salmeterol (FSC) on airway inflammation in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 44s Year: 2004 Airway hyperresponsiveness and treatment effectiveness during a one year study of the combination of salmeterol and fluticasone propionate (FP) compared with FP and salmeterol alone in mild to moderate asthma Source: Eur Respir J 2002; 20: Suppl. 38, 386s Year: 2002 Control of airway inflammation is maintained in asthma patients following a 60% reduction in ICS dose with fluticasone propionate/salmeterol (FSC) compared with higher dose fluticasone propionate (FP) alone Source: Eur Respir J 2004; 24: Suppl. 48, 308s Year: 2004 Sputum eosinophilia and the response to inhaled corticosteroid (mometasone) in COPD Source: Eur Respir J 2004; 24: Suppl. 48, 62s Year: 2004 Comparison of salmeterol/fluticasone propionate (sal/fp) combination versus monotherapy with fluticasone propionate (fp) in patients with mild to moderate asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Effect of fluticasone furoate (FF)/vilanterol (VI) once daily (OD) on risk of severe exacerbations in asthma Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012 Fluticasone furoate, a novel inhaled corticosteroid (ICS), provides sustained protection against amp airway hyperresponsiveness (AHR) in mild asthma Source: Annual Congress 2009 - New drugs for airways disease Year: 2009 Fluticasone furoate (FF), an inhaled corticosteroid (ICS), demonstrates efficacy in asthma patients symptomatic on moderate doses of ICS therapy Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010 The effect of montelukast on eosinophil apoptosis: Induced sputum findings of patients with mild persistant asthma Source: Eur Respir J 2003; 22: Suppl. 45, 101s Year: 2003 Twice-daily fluticasone propionate (fp)/formoterol fumarate (fm) HFA PMDI combination therapy is safe, efficacious and reduces asthma exacerbations in patients with mild to moderate asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Fluticasone furoate (FF), an inhaled corticosteroid (ICS), is efficacious in asthma patients symptomatic on low doses of ICS therapy Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010 Twice-daily fluticasone propionate (fp)/formoterol fumarate (fm) HFA PMDI combination therapy is safe, efficacious and reduces asthma exacerbations in patients with moderate to severe asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009